Adjuvant durvalumab did not improve disease-free survival in patients with early-stage non-small cell lung cancer in the phase 3 BR.31 trial.

Source: Getty Images Perioperative durvalumab has “the potential to transform the standard of care” for patients with ...

NKTR-255 in combination with durvalumab following chemoradiation was well-tolerated in patients with non–small cell lung ...

While presenting the Union Budget for 2024-25 in the Lok Sabha, Finance Minister Nirmala Sitharaman proposed to cut customs ...

In a move aimed at providing relief to cancer patients, the National Pharmaceutical Pricing Authority (NPPA) has directed ...

In these patients, adding tremelimumab to durvalumab and chemotherapy resulted in higher overall response rates (42.9%) relative to patients who received durvalumab plus chemotherapy (30.2%) or ...

NPPA directs manufacturers to reduce MRP of anti-cancer drugs following government's tax exemptions and duty reductions.

Akeso begins patient enrollment in phase 3 trial of ivonescimab combination as first-line therapy for biliary tract tumours, compared to durvalumab: China Monday, November 4, 2024 ...

Treatment arms included standard chemotherapy alone, chemotherapy plus programmed death ligand 1 (PD-L1) inhibitor durvalumab, and chemotherapy plus durvalumab and cytotoxic T-lymphocyte ...

NPPA asks companies to revise MRP of three anti-cancer drugs and submit information: Gireesh Babu, New Delhi Tuesday, October 29, 2024, 16:15 Hrs [IST] The National Pharmaceutical ...

The government of India has mandated companies to reduce the prices of three anti-cancer drugs, Trastuzumab, Osimertinib, and ...

New Delhi- The government has asked the companies to reduce prices of three anti-cancer drugs to pass on the benefit of ...